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Summary. The value of exercise testing as a prognostic measure of disease severity 
in patients with chronic chest diseases (CCD) is becoming increasingly recognised. 
The aim of this study was to investigate changes in oxygen uptake ( 2OV
& ) during 
early recovery following maximal cardiopulmonary exercise testing (CPXT) in 
relation to functional capacity and markers of disease severity. Twenty-seven children 
with CCD (age 12.7 ± 3.1 y; 17 female) [19 children with Cystic fibrosis (CF) (age 
13.4 ± 3.1 y; 10 female) and 8 with other stable non-CF chest diseases (NON-CF) 
(age 11.1 ± 2.2 y; 7 female)] and 27 healthy controls (age 13.2 ± 3.3 y; 17 female) 
underwent CPXT on a cycle ergometer. On-line respiratory gas analysis measured 
2OV
&  before and during CPXT to peak 2OV
&  ( 2OV
&
peak), and during the first 10 min of 
recovery. Early 2OV
&  recovery was quantified by the time (s) to reach 50 % of the 
2OV
&
peak value. Early 2OV
&  recovery was correlated against spirometry [forced 
expiratory volume in 1 s (FEV1) and forced expiratory flow between 25 to 75 % of the 
forced vital capacity (FEF25-75)] and aerobic fitness ( 2OV
&
peak) as a measure of 
functional capacity. Disease severity was graded in the CF patients by the 
Shwachman score (SS). Compared to controls, children with CCD demonstrated a 
significantly reduced 2OV
&
peak (P = 0.011), FEV1 (P = 0.000), FEF25-75 (P = 0.000), 
and a significantly prolonged early 2OV
&  recovery (P = 0.024). In the CF patients the 
SS was significantly correlated with early 2OV
&  recovery (r = - 0.63, P = 0.004), 
FEV1 (r = 0.72, P = 0.001) and FEF25-75 (r = 0.57, P = 0.011). In the children with 
CCD, FEV1, FEF25-75 and BMI were not significantly correlated with 2OV
&
peak or 
early 2OV
&  recovery, indicating that lung function does not necessarily reflect aerobic 
fitness and the ability to recover from exercise in these patients. A significant 
relationship was found between 2OV
&
peak and early 2OV
&  recovery (r = - 0.39, P = 
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0.044) in the children with CCD, showing that a greater aerobic fitness corresponded 
with a faster recovery.   
Key words: chronic chest diseases, children, exercise testing, recovery, clinical 
measure 
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INTRODUCTION 
Exercise testing is a valuable tool for monitoring the physiological impact of chronic 
chest diseases (CCD). 
1
 Exercise testing is incorporated in some paediatric respiratory 
centres as part of an annual assessment of children with Cystic fibrosis (CF), 
2
 based 
on evidence demonstrating that aerobic and anaerobic exercise are limited, 
3
 and that 
this limitation is related to survival. 
4
  Peak oxygen uptake ( 2OV
&
peak) during maximal 
cardiopulmonary exercise testing (CPXT) is considered the ‘gold standard’ measure 
for assessing aerobic fitness, 
1
 and is an important measure for well-being and 
prognosis in CF. 
4,5
 Lung function measured by spirometry, 
6
 and 2OV
&
peak measured 
during CPXT 
7
 are commonly measured to assess functional capacity and disease 
severity in patients with CF. Limited data exists, however, regarding recovery 
parameters following exercise testing in children with CCD.  
 
During early recovery from exercise, phosphocreatine (PCr) levels are inversely 
proportional to the rate of oxygen uptake ( 2OV
& ), and dependent on the transport to 
and utilisation of oxygen (O2) within contracting muscle. 
8,9
 The importance of O2 in 
the resynthesis of PCr has been previously reported. 
10-13
 Anaerobic glycolysis ceases 
at the termination of peak exercise, and oxidative phosphorylation provides the ATP 
required for PCr recovery. 
14
 In cardiac diseases where the transportation and 
utilisation of O2 in the contracting muscle is adversely affected, PCr recovery time has 
been reported to be prolonged following exercise, 
15-18
 whereas, a faster PCr recovery 
time has been demonstrated in healthy trained individuals. 
19
 The rate of PCr 
resynthesis during recovery from exercise is, therefore, a reflection of oxidative 
capacity, and can be inferred from 2OV
&  measurements in children. 
20
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We hypothesised that PCr resynthesis, as reflected by the 2OV
&  during early recovery 
from CPXT, is an index of the efficiency of maximal oxidative rate, and 1) will be 
prolonged in children with CCD compared to healthy controls, and 2) serve as an 
index of disease severity. Therefore, the aims of the study are to assess the 2OV
&  
responses during early recovery from CPXT in children with CCD and healthy 
controls, and explore the relationships with markers of functional capacity and disease 
severity in children with CCD. 
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MATERIALS AND METHODS 
Participants 
Twenty-seven children with CCD participated in the study (age 12.7 ± 3.1 y; 17 
female). For further analysis the children with CCD were divided into two diagnostic 
groups. One group consisted of 19 children with CF (age 13.4 ± 3.1 y; 10 female), and 
the other group consisted of 8 children with other stable non-CF chest diseases (NON-
CF) (age 11.1 ± 2.2 y; 7 female) [5 Non-CF bronchiectasis; 2 Primary ciliary 
dyskinesia; 1 Post-adenoviral obliterative bronchiolitis]. Twenty-seven healthy 
controls (age 13.2 ± 3.3 y; 17 female) free from any musculoskeletal, cardiovascular 
and pulmonary diseases that would compromise exercise performance were recruited 
from local schools and colleges in Devon, U.K. The controls were individually pair 
matched to the children with CCD for stature, body mass and pubertal maturity. 
 
All participants volunteered for the study and written informed consent and assent 
was obtained from parents and participants, respectively. All children with CCD 
attended the outpatient clinic of the Royal Devon and Exeter NHS Foundation Trust 
Hospital. All children with CCD were clinically stable at the time of CPXT, with no 
symptomatic deterioration over the preceding month. None had musculoskeletal 
conditions that would compromise exercise performance. Diagnosis of CF was based 
on clinical features supported by an abnormal sweat test (sweat chloride > 60 mmol
.
L) 
and in 17/19 diagnostic genotyping. Pubertal staging was assessed during routine 
outpatient clinic assessment by a trained nurse and classified as pre-, peri- and post- 
pubertal. 
21
 The study was approved by the NHS Local Research Ethics Committee.  
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Maximal Cardiopulmonary Exercise Testing (CPXT) 
Infection control measures to prevent cross-infection were followed. Children with 
CCD were segregated in both waiting areas and testing places. Both equipment and 
the testing environment were cleaned using appropriate bacteriocidal wipes and 
solutions after each use.  
 
Before CPXT all participants were instructed not to consume food or caffeine 2 hrs 
before and wear light comfortable clothes suitable for exercising on a cycle. All 
participants were also asked not to perform any strenuous exercise during 48 hrs prior 
to the test time. Maximal cardiopulmonary exercise testing was performed on a cycle 
ergometer (Excaliber Sport; Lode, Groningen, The Netherlands) using a ramp 
protocol, commencing with unloaded pedalling for 2 min and then 10 W increases 
were made incrementally every min. All participants pedalled at a cadence of 70 ± 5 
rpm and encouraged to continue until voluntary exhaustion. Peak oxygen uptake was 
determined by satisfying the following criteria; a respiratory exchange ratio > 1.06; 
heart rate > 95 % age related predicted maximum; scores of 8 – 10 after exercise on a 
children’s effort rating table (CERT); and clinically observed signs of facial flushing, 
sweating and tachypnoea.  
 
An on-line metabolic gas analyser (Cortex Metalyzer; Cortex Medical, Leipzig, 
Germany) measured 2OV
&  continuously. The system was calibrated with standard gas 
of known concentration before each test. Gas measurements were collected in the 
upright position before and during CPXT to 2OV
&
peak, and during the first 10 min of 
recovery using a 10 s moving average. Peak oxygen uptake was calculated as the 
highest recorded 30 s stationary average value during the CPXT. 
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Assessment of Functional Capacity 
Peak oxygen uptake and lung function were used as markers of functional capacity. 
Peak oxygen uptake was used as a measure of aerobic fitness and expressed relative to 
body mass (mL
.
kg
-1.
min
-1
). Lung function was assessed by forced expiratory volume 
in 1 s (FEV1), and forced expiratory flow between 25 to 75 % of the forced vital 
capacity (FEF25-75). All lung function measurements were expressed as % predicted, 
using appropriate reference data. 
22
 Each participant’s lung function was measured 
before the start of the CPXT. The forced expiratory manoeuvre was performed as 
recommended by the British Thoracic Society (1994) guidelines for the measurement 
of respiratory function, 
23
 recording the best of three consistent exhalations, using an 
electronic spirometer (Microloop ML3535; Numed, Sheffield, UK). 
 
Assessment of Early 2OV
&  Recovery 
Early 2OV
&  recovery time was quantified by the time in seconds (s) from the cessation 
of exercise to reach 50 % of the 2OV
&
peak value. This method has been described in 
previous studies to assess early 2OV
&  recovery in patients with cardiac diseases. 
24-26
 
 
Assessment of Disease Severity for the Cystic Fibrosis Patients 
The Shwachman score (SS) was used to grade disease severity in the CF patients, and 
was recorded prior to CPXT by the patient’s clinician. The SS scores four separate 
aspects of the disease profile, general activity, physical examination, nutritional status 
and chest radiographic findings, using the most recent routine annual review chest x-
ray. Each disease profile is given an equal weighting of 25 points. A total of 100 
points represents a perfect score of health. 
27
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Data Analysis 
Data were analysed using the Statistical Package for the Social Sciences (SPSS; 
version 11.0, Chicago, IL). The independent t-test was used for the comparison of the 
anthropometric and physiological data between children with CCD and controls. The 
Pearson product moment correlation was used to assess the association between 2OV
&  
indexes and parameters of functional capacity and disease severity. Statistical 
significance was set a priori at P < 0.05. 
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RESULTS 
The anthropometric data in Table 1 shows no significant differences in stature, body 
mass, BMI and pubertal maturity between the children with CCD and controls. The 
lung function data (Table 1) showed when compared to controls, children with CCD 
demonstrated significantly reduced FEV1 (P = 0.000), FVC (P = 0.004), PEF (P = 
0.003), and FEF25-75 (P = 0.000). Data from the CPXT (Table 2) showed that 
compared to controls the children with CCD had a significantly lower 2OV
&
peak (P = 
0.011) and a significantly prolonged early 2OV
&  recovery (P = 0.024). Other CPXT 
data such as maximum workload (Wmax) was significantly lower (P = 0.009) in 
children with CCD compared to controls. Maximum heart rate (HRmax) did not differ 
significantly between children with CCD and controls during CPXT (Table 2).  
 
The correlation data (Table 3a) showed in the children with CCD, FEV1, FEF25-75 and 
BMI were not significantly correlated with 2OV
&
peak or early 2OV
&  recovery. A 
significant negative relationship between 2OV
&
peak and early 2OV
&  recovery (r = - 
0.39, P = 0.044), however, was found in the children with CCD (Table 3a and Figure 
1). Sub-group analysis within the children with CCD revealed, in the CF patients a 
significant negative correlation between the SS and early 2OV
&  recovery (r = - 0.63, P 
= 0.004) (Table 3a and Figure 2), and significant correlations were also shown 
between the SS and FEV1 (r = 0.72, P = 0.001) (Table 3a and Figure 3), and FEF25-75 
(r = 0.57, P = 0.011) (Table 3a). No significant correlation, however, was found 
between the SS and 2OV
&
peak in the CF patients (Table 3a). Between the CF and 
NON-CF patients no significant differences in 2OV
&
peak (P = 0.715) and early 2OV
&  
recovery (P = 0.755) were shown, despite the NON-CF patients demonstrating a 
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significantly reduced FEV1 (P = 0.044) compared to the CF patients. Table 3b shows 
the correlational relationships for the healthy control group, only BMI was found to 
be significantly correlated to recovery (r = 0.48, P = 0.011). 
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DISCUSSION 
The present study found that compared to controls, children with CCD demonstrated a 
significantly reduced 2OV
&
peak and prolonged early 2OV
&  recovery following CPXT. 
The metabolic cost of exercise results from both the performance of external work, 
and the demands of the O2 transportation system itself. This includes the work 
performed by the muscles of respiration and the enduring metabolic demand to restore 
homeostasis during recovery. 
28
 The rate of 2OV
&  during early recovery from exercise 
in children with CCD will be influenced by many disease factors. For example, as 
disease progresses there is an increase in dead space, 
29
 that necessitates an increase in 
total ventilation in order to keep alveolar ventilation constant. 
30,31
 Airway obstruction 
and air trapping would also reduce the rate of elimination of excess carbon dioxide 
formed during exercise, prolonging tachypnoea, which itself would increase the 
metabolic demand and which contributes to fatigue. 
32
 Delayed elimination of carbon 
dioxide would also impair the ability to compensate for alterations in acid-based 
status. 
33
 Furthermore, in patients with CF the correlation between thin section 
computed tomographic (CT) findings of lung parenchymal damage and exercise 
limitation is stronger than that between spirometry results, or BMI and exercise 
limitation. 
34
 The CF genotype has also been reported to be related to exercise 
tolerance. 
35
  
 
The lung function data from the present study showed that FEV1, FVC, PEF and 
FEF25-75 were all significantly reduced in children with CCD compared to controls. 
Forced expiratory volume in 1 s, FEF25-75 and BMI in the children with CCD, 
however, were not significantly correlated with 2OV
&
peak or early 2OV
&  recovery. 
Furthermore, the study showed that despite a significantly reduced FEV1 in the NON-
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CF patients compared to the CF patients, 2OV
&
peak and early 2OV
&  recovery were not 
significantly different between the two patient groups. These findings demonstrate, 
therefore, that exercise performance was similar between the NON-CF and CF 
patients, despite poorer lung function in the NON-CF patients. These finding may 
emphasise the physiological differences between the static nature of lung function 
testing and the dynamic nature of the cardiopulmonary system when exercising. It 
may also infer, however, the physiological differences between children with CF and 
other CCD, especially in regard to recent work which found that CF patients 
demonstrated reduced oxidative work efficiency in the skeletal muscle. 
36
  
 
Contrary to previous studies which have reported that reduced FEV1 is associated 
with lower 2OV
&
peak, 
29,37-41
 a non-significant relationship between lung function and 
2OV
&
peak in the children with CCD in the present study may provide further support to 
work which has reported that reduced aerobic performance is related to intrinsic 
abnormalities of skeletal muscle function. 
36,42-44
 Furthermore, a recent study reported 
that 2OV
&
peak and exercise duration during CPXT was not affected in patients with 
mild CF using added dead space, suggesting the CPXT is not limited by respiratory 
factors. 
45
 Moser et al. (2000) also found no significant correlations between variables 
reflecting exercise performance (e.g., 2OV
&
peak) and lung function measurements (e.g., 
FEV1) in children with CF. 
43
 This finding is also supported by Edwards et al. (2004), 
who reported no relationships between variables measured during exercise testing and 
lung function. 
46 
Peak oxygen uptake and early 2OV
&  recovery, however, were 
significantly related; indicating the greater the aerobic fitness of the patient the faster 
the rate of recovery. This relationship although significant, however, is still quite 
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weak (r = - 0.39, P = 0.044), and therefore, may indicate that the 2OV
&  recovery can 
not be explained predominantly by the 2OV
&
peak. However, the finding that 2OV
&
peak 
and early 2OV
&  recovery were not significantly correlated for the healthy control 
group accentuates the relative importance of aerobic fitness and recovery and their 
impact on children with CCD. 
 
In children with CF a significant relationship between early 2OV
&  recovery and the SS 
was found. Correlations between structural abnormalities of the lung scored on thin 
section CT images and exercise performance have been reported in patients with CF, 
and these relationships are stronger than that between spirometry results, or BMI and 
exercise limitation, 
34
 and may explain the relationship found in the present study. 
Forced expiratory volume in 1 s and FEF25-75 in the children with CF were also 
significantly related to the SS, confirming previous reports that lung function is 
correlated with disease severity and survival in CF patients. 
6,47,48
 No significant 
relationship between 2OV
&
peak and the SS in the CF patients was found in the present 
study. The 2OV
&
peak values for children with CF in this study are similar to published 
values of aerobic fitness for young CF patients of a similar age range. 
43,49,50
 A 
significant correlation between 2OV
&
peak and SS has been previously reported in adults 
with CF, 
51
 but not in children. The disease severity of the adult CF patients was 
greater than in the present study (71 ± 14 versus 80 ± 12, respectively) and 2OV
&
peak 
was lower (25 ± 7 versus 35 ± 8 mL
.
kg
-1.
min
-1
, respectively), which may have 
increased the likelihood of finding a significant relationship due to a greater 
heterogeneity of the correlated variables. 
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In conclusion, children with CCD in the present study had mild to moderate disease as 
interpreted by their lung function, and showed a reduced 2OV
&
peak and prolonged early 
2OV
&  recovery compared to a control group. The prolonged recovery may be an 
indication of reduced oxidative capacity for PCr resynthesis, attributed to impaired O2 
transportation and utilisation in the contracting muscle. Indeed, the present study 
showed that early 2OV
&  recovery was significantly related to the SS in children with 
CF, indicating that early 2OV
&  recovery is prolonged with increased disease severity. 
Lung function was not significantly related to 2OV
&
peak and early 2OV
&  recovery, and 
therefore may not accurately reflect the patient’s ability to exercise and recover. 
Disease in CF can progress significantly, as shown on thoracic high resolution CT 
scanning, despite lung function stability. 
52
 Exercise testing can therefore help to 
provide useful additional information about functional limitations and trends over 
time. 
53
 A recent study reported that higher aerobic fitness despite poor lung function 
is associated with a better prognosis. 
49
 The links between more detailed measures of 
exercise performance including recovery parameters, disease severity and quality of 
life deserve more attention and warrant further investigation.  
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TABLE 1 - Characteristics of the anthropometric and lung function data of the 
children with CCD (n = 27) and healthy controls (n = 27) 
 Children with 
CCD  
(n = 27 ) 
 
Healthy Controls  
(n = 27) 
P value 
Gender 
 
17 females, 10 
males 
 
17 females, 10 
males 
P = 1.000 
Age (y) 
 
12.7 ± 3.1 13.2 ± 3.3 P = 0.610 
Stature (m) 
 
1.48 ± 0.15 1.55 ± 0.15 P = 0.133 
Body mass (kg) 
 
41.7 ± 12.6 45.9 ± 13.3 P = 0.233 
BMI (kg
.
m
-2
) 
 
18.4 ± 2.9 18.8 ± 2.8 P = 0.589 
Pubertal maturity 
 
2 ± 1 2 ± 1 P = 0.625 
SS  
 
80 ± 12 N/A
ψ
  
FEV1  
(% predicted) 
 
82 ± 23 103 ± 12 P = 0.000** 
FVC  
(% predicted) 
 
88 ± 19 102 ± 15 P = 0.004** 
PEF  
(% predicted) 
 
78 ± 22 93 ± 11 P = 0.003** 
FEF25-75  
(% predicted) 
 
78 ± 31 105 ± 17 P = 0.000** 
Values are means ± SD. ** P < 0.01. BMI, body mass index; SS, Shwachman score; 
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak 
expiratory flow; FEF25-75, forced expiratory flow between 25 to 75 % of the forced 
vital capacity. 
ψ
The SS is a marker of disease severity for the CF patients only. 
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TABLE 2 - Characteristics of the maximal cardiopulmonary exercise testing 
data of the children with CCD (n = 27) and healthy controls (n = 27) 
 Children with 
CCD  
(n = 27 ) 
 
Healthy 
Controls  
(n = 27) 
P value 
2OV& peak (mL.kg-1.min-1) 
 
35 ± 8 42 ± 11 P = 0.011* 
Early 2OV& recovery (s) 
 
58 ± 16 50 ± 7 P = 0.024* 
HRmax (b.min-1) 
 
173 ± 26 183 ± 16 P = 0.103 
Wmax (W) 
 
121 ± 52 166 ± 67 P = 0.009** 
Values are means ± SD. *P < 0.05, ** P < 0.01. 2OV& peak, peak oxygen uptake; Early 
2OV& recovery, early oxygen uptake recovery; HRmax, maximum heart rate; Wmax, 
maximum workload. 
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TABLE 3a – Correlation data for the children with CCD (n = 27) 
 BMI FEV1  
(% predicted) 
 
FEF25-75 
(% predicted) 
 
2OV& peak 
(mL.kg-1.min-1) 
 
Early 2OV&  
recovery (s) 
 
SSψ  
 
 
BMI  r = 0.29 
(P = 0.141) 
r = 0.15 
(P = 0.470) 
r = 0.02 
(P = 0.927) 
r  = - 0.02 
(P = 0.904) 
 
r  = 0.00 
(P = 0.989) 
 
FEV1  
(% predicted) 
 
  r  = 0.89** 
(P = 0.000) 
 
r  = 0.18 
(P = 0.363) 
 
r  = - 0.30 
(P = 0.126) 
 
r  = 0.72** 
(P = 0.001) 
 
FEF25-75 
(% predicted) 
 
   r  = 0.08 
(P = 0.708) 
 
r  = - 0.20 
(P = 0.328) 
 
r  = 0.57* 
(P = 0.011) 
 
2OV& peak 
(mL.kg-1.min-1) 
 
    r  = - 0.39* 
(P = 0.044) 
 
r  = 0.39 
(P = 0.095) 
 
Early 2OV&  
recovery (s) 
 
     r  = -0.63** 
(P = 0.004) 
 
SSψ 
 
      
*P < 0.05, ** P < 0.01. BMI, body mass index; FEV1, forced expiratory volume in 1 s; FEF25-75, 
forced expiratory flow between 25 to 75 % of the forced vital capacity; 2OV& peak, peak oxygen 
uptake; Early 2OV& recovery, early oxygen uptake recovery; SS, Shwachman score. 
ψThe SS is a 
marker of disease severity for the CF patients only. 
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TABLE 3b – Correlation data for the healthy controls (n = 27) 
 BMI FEV1  
(% predicted) 
 
FEF25-75 
(% predicted) 
 
2OV& peak  
(mL.kg-1.min-1) 
 
Early 2OV&  
recovery (s) 
 
BMI  r = 0.35 
(P = 0.072) 
r = - 0.33 
(P = 0.093) 
r = - 0.25 
(P = 0.202) 
r  =  0.48** 
(P = 0.011) 
 
FEV1  
(% predicted) 
 
  r  = 0.24 
(P = 0.224) 
 
r  = - 0.30 
(P = 0.129) 
 
r  =  0.21 
(P = 0.284) 
 
FEF25-75 
(% predicted) 
 
   r  = - 0.09 
(P = 0.670) 
 
r  = - 0.03 
(P = 0.892) 
 
2OV& peak  
(mL.kg-1.min-1) 
 
    r  = - 0.24 
(P = 0.219) 
 
Early 2OV&  
recovery (s) 
 
     
** P < 0.01. BMI, body mass index; FEV1, forced expiratory volume in 1 s; FEF25-75, forced 
expiratory flow between 25 to 75 % of the forced vital capacity; 2OV& peak, peak oxygen uptake; 
Early 2OV& recovery, early oxygen uptake recovery. 
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FIGURE 1 - The relationship between 2OV& peak and early 2OV&  recovery in the 
children with CCD (n = 27) 
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FIGURE 2 - The relationship between the Shwachman score and early 2OV&  
recovery in the CF patients (n = 19) 
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FIGURE 3 - The relationship between the Shwachman score and FEV1 in the CF 
patients (n = 19) 
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Summary. The value of exercise testing as a prognostic measure of disease severity 
in patients with chronic chest diseases (CCD) is becoming increasingly recognised. 
The aim of this study was to investigate changes in oxygen uptake ( 2OV
& ) during 
early recovery following maximal cardiopulmonary exercise testing (CPXT) in 
relation to functional capacity and markers of disease severity. Twenty-seven children 
with CCD (age 12.7 ± 3.1 y; 17 female) [Nineteen  19 children with Cystic fibrosis 
(CF) (age 13.4 ± 3.1 y; 10 female) and 8 with other stable non-CF chest diseases 
(NON-CF) with other stable CCD (age 11.1 ± 2.2 y; 7 female)] and 27 healthy 
controls (age 13.2 ± 3.3 y; 17 female) underwent CPXT on a cycle ergometer. On-line 
respiratory gas analysis measured 2OV
&  before and during CPXT to peak 2OV
&  
( 2OV
&
peak), and during the first 10 min of recovery. Early 2OV
&  recovery was 
quantified by the time (s) to reach 50 % of the 2OV
&
peak value. Early 2OV
&  recovery 
was correlated against lung function spirometry [forced expiratory volume in 1 s 
(FEV1) and forced expiratory flow between 25 to 75 % of the forced vital capacity 
(FEF25-75)] and aerobic fitness ( 2OV
&
peak) as a measure of functional capacity. Disease 
severity was graded in the CF group patients by the Shwachman score (SS). 
Compared to controls, children with CCD demonstrated a significantly reduced 
2OV
&
peak (P = 0.011), FEV1 (P = 0.000), FEF25-75 (P = 0.000), and a significantly 
prolonged early 2OV
&  recovery (P = 0.024). In the CF group patients the SS was 
significantly correlated with early 2OV
&  recovery (r = - 0.63, P = 0.004), FEV1 (r = 
0.72, P = 0.001) and FEF25-75 (r = 0.57, P = 0.011). The ratio 2OV
&
peak (mL
.
min
-1.
kg
-1
) 
/ early 2OV
&  recovery (s) (r = 0.50, P = 0.028) used in this study as a composite 
measure of exercise performance and recovery. In the children with CCD, FEV1, 
FEF25-75 and BMI were not significantly correlated with 2OV
&
peak or early 2OV
&  
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recovery, indicating that lung function does not necessarily reflect aerobic fitness and 
the ability to recover from exercise in these patients. A significant relationship was 
found between 2OV
&
peak and early 2OV
&  recovery (r = - 0.39, P = 0.044) in the 
children with CCD, showing that a greater aerobic fitness corresponded with a faster 
recovery.  In the CCD group FEV1 was significantly lower compared to the CF group 
(68 ± 21 vs 87 ± 21 % predicted, respectively; P = 0.044), however, no significant 
differences were found between the groups for 2OV
&
peak (35.9 ± 8.4 vs 34.7 ± 8.0 
mL
.
kg
-1.
min
-1
, respectively; P = 0.715) and early 2OV
&  recovery (56 ± 16 vs 58 ± 16 s, 
respectively; P = 0.755). In children with CF, early 2OV
&  recovery following CPXT 
and FEV1 are significantly related to disease severity. In children with CF and other 
CCD, however, FEV1 does not fully reflect the ability to exercise and recover. 
Key words: chronic chest diseases, children, exercise testing, recovery, clinical 
measure 
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INTRODUCTION 
Exercise testing is a valuable tool for monitoring the physiological impact of chronic 
chest diseases (CCD). 
1
 Exercise testing is incorporated in some paediatric respiratory 
centres as part of an annual assessment of children with Cystic fibrosis (CF), 
2
 based 
on evidence demonstrating that aerobic and anaerobic exercise are limited, 
3
 and that 
this limitation is related to survival. 
4
  Peak oxygen uptake ( 2OV
&
peak) during maximal 
cardiopulmonary exercise testing (CPXT) is considered the ‘gold standard’ measure 
for assessing aerobic fitness, 
1
 and is an important measure for well-being and 
prognosis in CF. 
4,5
 Lung function measured by spirometry, 
6
 and 2OV
&
peak measured 
during CPXT 
7
 are commonly measured to assess functional capacity and disease 
severity in patients with CF. Limited data exists, however, regarding recovery 
parameters following exercise testing in children with CCD.  
 
During early recovery from exercise, phosphocreatine (PCr) levels are inversely 
proportional to the rate of oxygen uptake ( 2OV
& ), and dependent on the transport to 
and utilisation of oxygen (O2) within contracting muscle. 
8,9
 The importance of O2 in 
the resynthesis of PCr has been previously reported. 
10-13
 Anaerobic glycolysis ceases 
at the termination of peak exercise, and oxidative phosphorylation provides the ATP 
required for PCr recovery. 
14
 In cardiac diseases where the transportation and 
utilisation of O2 in the contracting muscle is adversely affected, PCr recovery time has 
been reported to be prolonged following exercise, 
15-18
 whereas, a faster PCr recovery 
time has been demonstrated in healthy trained individuals. 
19
 The rate of PCr 
resynthesis during recovery from exercise is, therefore, a reflection of oxidative 
capacity, and can be inferred from 2OV
&  measurements in children. 
20
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We hypothesised that PCr resynthesis, as reflected by the 2OV
&  during early recovery 
from CPXT, is an index of the efficiency of maximal oxidative rate, and 1) will be 
prolonged in children with CCD compared to healthy controls, and 2) serve as an 
index of disease severity. Therefore, the aims of the study are to assess the 2OV
&  
responses during early recovery from CPXT in children with CCD and healthy 
controls, and explore the relationships with markers of functional capacity and disease 
severity in children with CCD. 
Assessing exercise performance is a valuable tool in monitoring health-status in 
cardiopulmonary disease. 
1
 In chronic chest diseases (CCD), especially Cystic fibrosis 
(CF), exercise limitation is a mark of disease progression. 
21
 The measurement of 
peak oxygen uptake ( 2OV
&
peak) during exercise testing is a measure of aerobic 
functional capacity and may predict prognosis in patients with CF. 
4,22-24
 Various 
exercise tests are incorporated into routine assessments of patients in CF centres. 
25
 
Information regarding exercise performance in young patients with other CCD, 
however, is limited. 
 
Many studies in CF to date have concentrated on the measurement of 2OV
&
peak 
without considering measures of recovery. In adults, however, with heart disease 
26-30
 
and chronic obstructive pulmonary disease (COPD), 
31
 the prognostic value of 
recovery measures following exercise testing have been investigated. Oxygen uptake 
( 2OV
& ) recovery time increases as ischaemic heart disease progresses 
28
 and is 
prolonged in adults with heart failure 
29
 when compared to controls 
27
 and COPD. 
31
 
The metabolic cost of exercise results from both the performance of external work, 
and the demands of the oxygen transport system itself, including the work performed 
by the muscles for respiration and persistent hypermetabolism recognised during 
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recovery. 
32
 During early recovery, oxygen is primarily required for the re-
phosphorylation of creatine in skeletal muscles. The early rapid decline in 2OV
&  
marks replenishment of muscle energy stores and the rate is an index of the efficiency 
of oxidative ATP resynthesis and this efficiency is reflected in an individual’s 
functional capacity or ability to sustain repeated bouts of physical activity. Children 
with CF have less efficient oxidative ATP synthesis 
33
 which could prolong the early 
2OV
&  recovery period after exercise. 
 
Assessing the rate at which the patient recovers from exercise may provide additional 
information on current health-status. Following exercise the rate of recovery from the 
increased oxygen requirements in children with lung disease will be influenced by 
many disease factors including th  presence of chronic infection and numerous 
physiological abnormalities which impair gas exchange and increase the work of 
breathing. An increase in dead space as the disease progresses, 
34
 necessitates an 
increase in total ventilation in order to keep alveolar ventilation constant. 
35,36
 Airway 
obstruction and air trapping reduces the rate of elimination of excess carbon dioxide 
formed during exercise, prolonging tachypnoea, which itself increases the metabolic 
demand for a given task and which contributes to fatigue. 
37
 Delayed elimination of 
carbon dioxide also impairs the ability to compensate for alterations in acid-based 
status. 
38
 
 
The aim of this study, therefore, was to explore the relationship of markers of 
functional capacity and disease severity with early 2OV
&  recovery in children with CF 
and other CCD. We hypothesised that early 2OV
&  recovery following maximal 
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cardiopulmonary exercise testing (CPXT) is significantly related to other measures of 
disease severity and functional capacity in children with CF and other CCD. 
 
MATERIALS AND METHODS 
Participants 
Twenty-seven children with CCD participated in the study (age 12.7 ± 3.1 y; 17 
female). For further analysis the children with CCD were divided into two diagnostic 
groups. One group consisted of 19 children with CF (age 13.4 ± 3.1 y; 10 female), and 
the other group consisted of 8 children with other stable non-CF chest diseases (NON-
CF) (age 11.1 ± 2.2 y; 7 female) CCD diagnostic groups. The CF group consisted of 
19 children (age 13.4 ± 3.1 y; 10 female), and the CCD group consisted of eight 
children (age 11.1 ± 2.2 y; 7 female) [5 Non-CF bronchiectasis; 2 Primary ciliary 
dyskinesia; 1 Post-adenoviral obliterative bronchiolitis]. Twenty-seven healthy 
controls (age 13.2 ± 3.3 y; 17 female) free from any musculoskeletal, cardiovascular 
and pulmonary diseases that would compromis  exercise performance were recruited 
from local schools and colleges in Devon, U.K. The controls were individually pair 
matched to the children with CCD for stature, body mass and pubertal maturity. 
 
All participants volunteered for the study and written informed consent and assent 
was obtained from parents and participants, respectively. All children with CCD 
volunteered for the study and attended the outpatient clinic of the Royal Devon and 
Exeter NHS Foundation Trust Hospital. Written informed consent and assent was 
obtained from parents and children, respectively. All children with CCD were 
clinically stable at the time of CPXT, with no symptomatic deterioration over the 
preceding month. None had musculoskeletal conditions that would compromise 
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exercise performance. Diagnosis of CF was based on clinical features supported by an 
abnormal sweat test (sweat chloride > 60 mmol
.
L) and in 17/19 diagnostic 
genotyping. Pubertal staging was assessed during routine outpatient clinic assessment 
by a trained nurse and classified as pre-, peri- and post- pubertal. 
39
 The study was 
approved by the NHS Local Research Ethics Committee. Table 1 shows the 
anthropometric and physiological data of the CF and CCD. 
 
Maximal Cardiopulmonary Exercise Testing (CPXT) 
Infection control measures to prevent cross-infection were followed. Children with 
CCD were segregated in both waiting areas and testing places. Both equipment and 
the testing environment were cleaned using appropriate bacteriocidal wipes and 
solutions after each use.  
 
Before CPXT all participants were instructed not to consume food or caffeine 2 hrs 
before and wear light comfortable clothes suitable for exercising on a cycle. All The 
participants were also asked not to perform any strenuous exercise during 48 hrs prior 
to the test time. Maximal cardiopulmonary exercise testing was performed on a cycle 
ergometer (Excaliber Sport; Lode, Groningen, The Netherlands) using a ramp 
protocol, commencing with unloaded pedalling for 2 min and then 10 W increases 
were made incrementally every min. All participants pedalled at a cadence of 70 ± 5 
rpm and encouraged to continue until voluntary exhaustion. Peak oxygen uptake was 
determined by satisfying the following criteria; a respiratory exchange ratio > 1.06; 
heart rate > 95 % age related predicted maximum; scores of 8 – 10 after exercise on a 
children’s effort rating table (CERT); and clinically observed signs of facial flushing, 
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sweating and tachypnoea. Pulse oximetry, taken via the finger, recorded continuous 
oxygen saturation (Tuffsat; Datex-Ohmeda, Colorado, USA). 
 
An on-line metabolic gas analyser (Cortex Metalyzer; Cortex Medical, Leipzig, 
Germany) measured 2OV
&  continuously. The system was calibrated with standard gas 
of known concentration before each test. Gas measurements were collected in the 
upright position before and during CPXT to 2OV
&
peak, and during the first 10 min of 
recovery using a 10 s moving average. Peak oxygen uptake was calculated as the 
highest recorded 30 s stationary average value during the CPXT. 
 
Assessment of Functional Capacity 
Peak oxygen uptake and lung function were used as markers of functional capacity. 
Peak oxygen uptake was used as a measure of aerobic fitness and expressed relative to 
body mass (mL
.
kg
-1.
min
-1
). Lung function was assessed by forced expiratory volume 
in 1 s (FEV1), and forced expiratory flow between 25 to 75 % of the forced vital 
capacity (FEF25-75). All lung function measurements were and expressed as % 
predicted, using appropriate reference data. 
40
 Each participant’s lung function was 
measured before the start of the CPXT. The forced expiratory manoeuvre was 
performed as recommended by the British Thoracic Society (1994) guidelines for the 
measurement of respiratory function, 
41
 recording the best of three consistent 
exhalations, using an electronic spirometer (Microloop ML3535; Numed, Sheffield, 
UK). 
 
Assessment of Early 2OV
&  Recovery 
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Early 2OV
&  recovery time was quantified by the time in seconds s from the cessation 
of exercise to reach 50 % of the 2OV
&
peak value. This method has been described in 
previous studies to assess early 2OV
&  recovery in patients with cardiac diseases 
chronic heart failure. 
26,27,42
 
 
Assessment of Disease Severity for the Cystic Fibrosis Patients 
The Shwachman score (SS) was used to grade disease severity in the CF patients 
group, and was recorded prior to CPXT by the patient’s clinician. The SS scores four 
separate aspects of the disease profile, general activity, physical examination, 
nutritional status and chest radiographic findings, using the most recent routine annual 
review chest x-ray. Each disease profile is given an equal weighting of 25 points. A 
total of 100 points represents a perfect score of health. 
43
 
 
Assessment of Composite Measure of Exercise Performance for the Cystic 
Fibrosis Group 
In this study a ratio of 2OV
&
peak (mL
.
min
-1.
kg
-1
) / early 2OV
&  recovery (s) was also 
used as a composite measure of exercise performance and recovery in the CF group. 
 
Data Analysis 
Data were analysed using the Statistical Package for the Social Sciences (SPSS; 
version 11.0, Chicago, IL). The independent t-test was used for the comparison of the 
anthropometric and physiological data between children with CCD and controls the 
CF and groups. The Pearson product moment correlation was used to assess the 
association between 2OV
&  indexes and parameters of functional capacity and disease 
severity. Statistical significance was set a priori at P < 0.05. 
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RESULTS 
The anthropometric data in Table 1 shows no significant differences in stature, body 
mass, BMI and pubertal maturity between the children with CCD and controls. The 
lung function data (Table 1) showed when compared to controls, children with CCD 
demonstrated significantly reduced FEV1 (P = 0.000), FVC (P = 0.004), PEF (P = 
0.003), and FEF25-75 (P = 0.000). Data from the CPXT (Table 2) showed that 
compared to controls the children with CCD had a significantly lower 2OV
&
peak (P = 
0.011) and a significantly prolonged early 2OV
&  recovery (P = 0.024). Other CPXT 
data such as maximum workload (Wmax) was significantly lower (P = 0.009) in 
children with CCD compared to controls. Maximum heart rate (HRmax) did not differ 
significantly between children with CCD and controls during CPXT (Table 2).  
 
The correlation data (Table 3a) showed in the children with CCD, FEV1, FEF25-75 and 
BMI were not significantly correlated with 2OV
&
peak or early 2OV
&  recovery. A 
significant negative relationship between 2OV
&
peak and early 2OV
&  recovery (r = - 
0.39, P = 0.044), however, was found in the children with CCD (Table 3a and Figure 
1). Sub-group analysis within the children with CCD revealed, in the CF patients a 
significant negative correlation between the SS and early 2OV
&  recovery (r = - 0.63, P 
= 0.004) (Table 3a and Figure 2), and significant correlations were also shown was 
also present between the SS and FEV1 (r = 0.72, P = 0.001) (Table 3a and Figure 3), 
and FEF25-75 (r = 0.57, P = 0.011) (Table 3). No significant correlation, however, was 
found between the SS and 2OV
&
peak (Table 2) in the CF patients (Table 3a). Between 
the CF and NON-CF patients no significant differences in 2OV
&
peak (P = 0.715) and 
early 2OV
&  recovery (P = 0.755) were shown, despite the NON-CF patients 
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demonstrating a significantly reduced FEV1 (P = 0.044) compared to the CF patients. 
Table 3b shows the correlational relationships for the healthy control group, only BMI 
was found to be significantly correlated to recovery (r = 0.48, P = 0.011). 
 
There were no significant differences between the CF and CCD groups in age, stature 
and pubertal maturity (Table 1). Body mass, body mass index and FEV1 were 
significantly greater in the CF group than in the CCD group (Table 1). No significant 
differences were found between the CF group and CCD group in 2OV
&
peak and early 
2OV
&  recovery (Table 1). No significant differences in the pulse oximetry data 
between the CF and CCD groups were found before or at the termination of CPXT 
(Table 1), but a significant fall in oxygen saturation before to the termination of 
CPXT was found in the CF group (97 ± 1 vs 94 ± 2 %, respectively; P = 0.001) and 
CCD group (97 ± 0.5 % vs 96 ± 1 %, respectively; P = 0.015). 
 
In the CF group a significant negative correlation was found between the SS and early 
2OV
&  recovery (Table 2 and Figure 1), and a significant correlation was also present 
between the SS and FEV1 (Table 2 and Figure 2). No significant correlation was 
found between the SS and 2OV
&
peak (Table 2). Furthermore, amongst the children with 
CF, the ratio of 2OV
&
peak / early 2OV
&  recovery was significantly correlated with the 
SS (Table 2 and Figure 3), but not with FEV1 (Table 2).  
 
In the CCD group early 2OV
&  recovery had a significant negative relationship with 
2OV
&
peak (Table 3 and Figure 4), but not in the CF group (Table 2). No signification 
correlations were found between early 2OV
&  recovery and FEV1 in either the CF 
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group (Table 2) or the CCD group (Table 3). Similarly, FEV1 and 2OV
&
peak were not 
found to be significantly related in either the CF group (Table 2) or CCD group 
(Table 3). 
 
DISCUSSION 
The present study found that compared to controls, children with CCD demonstrated a 
significantly reduced 2OV
&
peak and prolonged early 2OV
&  recovery following CPXT. 
The metabolic cost of exercise results from both the performance of external work, 
and the demands of the O2 transportation system itself. This includes the work 
performed by the muscles of respiration and the enduring metabolic demand to restore 
homeostasis during recovery. 
32
 The rate of 2OV
&  during early recovery from exercise 
in children with CCD will be influenced by many disease factors. For example, as 
disease progresses there is an increase in dead space, 
34
 that necessitates an increase in 
total ventilation in order to keep alveolar ventilation constant. 
35,36
 Airway obstruction 
and air trapping would also reduce the rate of elimination of excess carbon dioxide 
formed during exercise, prolonging tachypnoea, which itself would increase the 
metabolic demand and which contributes to fatigue. 
37
 Delayed elimination of carbon 
dioxide would also impair the ability to compensate for alterations in acid-based 
status. 
38
 Furthermore, in patients with CF the correlation between thin section 
computed tomographic (CT) findings of lung parenchymal damage and exercise 
limitation is stronger than that between spirometry results, or BMI and exercise 
limitation. 
44
 The CF genotype has also been reported to be related to exercise 
tolerance. 
45
 The aim of this study was to investigate if early 2OV
&  recovery following 
CPXT was associated with disease severity and functional capacity in children with 
CF, and functional capacity in those with other CCD.  
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The lung function data from the present study showed that FEV1, FVC, PEF and 
FEF25-75 were all significantly reduced in children with CCD compared to controls. 
Forced expiratory volume in 1 s, FEF25-75 and BMI in the children with CCD, 
however, were not significantly correlated with 2OV
&
peak or early 2OV
&  recovery. 
Furthermore, the study showed that despite a significantly reduced FEV1 in the NON-
CF patients compared to the CF patients, 2OV
&
peak and early 2OV
&  recovery were not 
significantly different between the two patient groups. These findings demonstrate, 
therefore, that exercise performance was similar between the NON-CF and CF 
patients, despite poorer lung function in the NON-CF patients. These finding may 
emphasise the physiological differences between the static nature of lung function 
testing and the dynamic nature of the cardiopulmonary system when exercising. It 
may also infer, however, the physiological differences between children with CF and 
other CCD, especially in regard to recent work which found that CF patients 
demonstrated reduced oxidative work efficiency in the skeletal muscle. 
33
  
 
Contrary to previous studies which have reported that reduced FEV1 is associated 
with lower 2OV
&
peak, 
21,34,46-49
 a non-significant relationship between lung function and 
2OV
&
peak in the children with CCD in the present study may provide further support to 
work which has reported that reduced aerobic performance is related to intrinsic 
abnormalities of skeletal muscle function. 
33,50-52
 Furthermore, a recent study reported 
that 2OV
&
peak and exercise duration during CPXT was not affected in patients with 
mild CF using added dead space, suggesting the CPXT is not limited by respiratory 
factors. 
53
 Moser et al. (2000) also found no significant correlations between variables 
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reflecting exercise performance (e.g., 2OV
&
peak) and lung function measurements (e.g., 
FEV1) in children with CF. 
51
 This finding is also supported by Edwards et al. (2004), 
who reported no relationships between variables measured during exercise testing and 
lung function. 
54
 Peak oxygen uptake and early 2OV
&  recovery, however, were 
significantly related; indicating the greater the aerobic fitness of the patient the faster 
the rate of recovery. This relationship although significant, however, is still quite 
weak (r = - 0.39, P = 0.044), and therefore, may indicate that the 2OV
&  recovery can 
not be explained predominantly by the 2OV
&
peak. However, the finding that 2OV
&
peak 
and early 2OV
&  recovery were not significantly correlated for the healthy control 
group accentuates the relative importance of aerobic fitness and recovery and their 
impact on children with CCD. 
 
In children with CF a significant relationship between early 2OV
&  recovery and the SS 
was found. Correlations between structural abnormalities of the lung scored on thin 
section CT images and exercise performance have been reported in patients with CF, 
and these relationships are stronger than that between spirometry results, or BMI and 
exercise limitation, 
44
 and may explain the relationship found in the present study. 
Based on the results of this study early 2OV
&  recovery has value as an objective 
measure of disease severity in children with CF. Forced expiratory volume in 1 s and 
FEF25-75 in the children with CF were also significantly related to the SS A significant 
relationship was also found in the CF group between FEV1 and the SS, confirming 
previous reports that lung function is correlated with disease severity and survival in 
CF patients. 
6,55,56
 This study found No significant relationship between 2OV
&
peak and 
the SS in the CF patients group was found in the present study. The 2OV
&
peak values 
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for children with CF in this study are similar to published values of aerobic fitness for 
young CF patients of a similar age range. 
23,24,51
 A significant correlation between 
2OV
&
peak and SS has been previously reported in adults with CF, 
57
 but not in children.  
The disease severity of the adult CF patients was greater than in the present study (71 
± 14 versus 80 ± 12, respectively) and 2OV
&
peak was lower (25 ± 7 versus 35 ± 8 
mL
.
kg
-1.
min
-1
, respectively), which may have increased the likelihood of finding a 
significant relationship due to a greater heterogeneity of the correlated variables. 
 
No significant differences in 2OV
&
peak or early 2OV
&  recovery between the CF and 
CCD groups were found despite the children in the CCD group having a significantly 
reduced FEV1. This finding signifies that static airway obstruction as measured by 
FEV1 for the range of values in this study did not affect either group’s ability to utilise 
oxygen either during or immediately following CPXT. Furthermore, it emphasises the 
physiological differences between the static nature of pulmonary function testing and 
the dynamic nature of the pulmonary/respiratory system when exercising. This may 
explain why FEV1 was not significantly related to 2OV
&
peak and early 2OV
& recovery in 
either groups. Therefore, this study found that in children with CF and other CCD, 
FEV1 is a poor predictor of exercise performance and recovery.  
 
A significant relationship was found between early 2OV
&  recovery and 2OV
&
peak in the 
CCD group but not the CF group. Therefore, 2OV
&
peak is a good predictor of early 
2OV
&  recovery in children with CCD but not in children with CF. This finding may 
reflect more disease variables and physiological differences between the CF and CCD 
groups. Published work has reported that impaired exercise performance in young CF 
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patients is partly due to pathophysiological factors in skeletal muscle that cannot be 
readily attributed to nutritional factors. 
51,58
 Intrinsic metabolic abnormalities such as a 
reduced metabolic efficiency (i.e., less oxidative ATP turnover for muscle mechanical 
work) may exist in the muscle of young CF patients, which contribute to a reduced 
exercise performance. 
58
 
 
Using the ratio of 2OV
&
peak / early 2OV
&  recovery as a composite measure of exercise 
performance, a significant correlation was found with the SS in the CF group and, 
therefore, may be an objective measure of disease severity. Recovery time may refine 
the 2OV
&
peak measure, and the ratio of the two measures may provide a comprehensive 
exercise performance score. For example, where patients with higher aerobic capacity 
and who recover more quickly have greater physical ability than those with high 
aerobic capacity but slower recovery, or those with low aerobic capacity and slow 
recovery. More research, however, is needed to verify this measure and the data in 
this study is preliminary. 
 
Many studies of therapeutic interventions use lung function variables as the primary 
outcome. 
59-63
 Disease in CF can progress as shown on thoracic High Resolution 
Computerised Tomography Scanning despite lung function stability. 
64
 Exercise 
parameters may provide a more integrated outcome measure. Exercise involves the 
amalgamation of respiratory, cardiovascular, metabolic, nutritional and psychological 
systems and therefore measures of performance are more likely to reflect health-status 
than a single static test such as spirometric lung function. Exercise performance as 
measured by 2OV
&
peak has been shown to have a closer correlation with prospective 
mortality than resting lung function in CF. 
4
 Exercise testing can provide useful 
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additional information about functional limitations and trends over time. 
65
 The links 
between more detailed measures of exercise performance including recovery 
parameters, disease severity and quality of life deserve more attention. Objective 
measures may be more accurate in predicting prognosis and mapping progress and 
response to treatments than more subjective scoring systems of well-being. Peak 
oxygen uptake alone may have limitations and a more composite measure of exercise 
performance that includes the rate of recovery may be more meaningful. 
 
In conclusion, children with CCD in the present study had mild to moderate disease as 
interpreted by their lung function, and showed a reduced 2OV
&
peak and prolonged early 
2OV
&  recovery compared to a control group. The prolonged recovery may be an 
indication of reduced oxidative capacity for PCr resynthesis, attributed to impaired O2 
transportation and utilisation in the contracting muscle. Indeed, the present study 
showed that early 2OV
&  recovery was significantly related to the SS in children with 
CF, indicating that early 2OV
&  recovery is prolonged with increased disease severity. 
Lung function was not significantly related to 2OV
&
peak and early 2OV
&  recovery, and 
therefore may not accurately reflect the patient’s ability to exercise and recover. 
Indeed, disease in CF can progress significantly, as shown on thoracic high resolution 
CT scanning, despite lung function stability. 
64
 Exercise testing can help to provide 
useful additional information about functional limitations and trends over time. 
65
 A 
recent study reported that higher aerobic fitness despite poor lung function is 
associated with a better prognosis. 
23
 The links between more detailed measures of 
exercise performance including recovery parameters, disease severity and quality of 
life deserve more attention and warrant further investigation. Furthermore, the present 
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study found that early 2OV
&  recovery and FEV1 were both significantly related to 
disease severity, as assessed by the SS, in children with CF. Therefore, both early 
2OV
&  recovery and FEV1 may be used to predict disease severity in children with CF. 
Furthermore, our data revealed that despite a significant reduction in FEV1 in the 
CCD group compared to the CF group, there were no significant differences in 
2OV
&
peak and early 2OV
&  recovery between the two groups, indicating that spirometric 
pulmonary function does not necessarily reflect a CCD patient’s exercise ability. A 
recent study reported that higher aerobic fitness despite poor lung function is 
associated with a better prognosis. 
23
 Therefore, measures of exercise performance 
and recovery should be considered as a routine test as they are likely to enhance the 
comprehensive assessment of patient well-being 
5
.  
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